Deposition diseases cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

Aref Albakri*
St-Marien hospital Bonn Venusberg, Department of internal medicine, Bonn, Germany

Abstract
Cardiomyopathies (CM) refer to a group of myocardial diseases associated with significant morbidity and mortality despite marked improvements in medical and device therapies. Efforts to improve therapeutic efficacy and minimize mortality have seen an increase in research for aetiology-specific therapies. A rare but an important aetiology of CM is depositional diseases, which present with a wide spectrum of clinical manifestations depending on the type, location and stage of the disease. It has an unfavourable prognosis and often results in death if left untreated. In the initial stages, it is asymptomatic presenting as diastolic dysfunction and restrictive filling pattern with preserved or mildly depressed systolic function. In the later stages, the disease progresses into the dilated phenotype with bi-ventricular dysfunction. Due to its varied clinical manifestations, diagnosis is often delayed. Except for cardiac amyloidosis, the lack of data on other deposition diseases undermines a holistic understanding of their role in the pathophysiology of CM. Although early diagnosis and targeted treatment may improve patient and clinical outcomes, the lack of clinical guidelines or proven therapies undermines the effectiveness of current clinical management strategies. This literature review and meta-analysis aggregates data on CM due to depositional diseases with a particular focus on pathophysiology, clinical presentation, diagnosis and clinical management. The intention is to improve clinical outcomes and minimize mortality in patients with CM secondary to depositional diseases.

Introduction
Deposition diseases refer to a diverse group of disorders resulting from the accumulation of substances in various body organs usually due to abnormal metabolism or degenerative phenomena occurring locally or systematically [1]. They are an uncommon cause of cardiomyopathy (CM) with sporadic reports of myocardial involvement in literature. The initial official recognition of the pathogenic role of deposition diseases in CMs appeared in the 2006 American Heart Association (AHA) scientific statement on contemporary definition and classification of dilated CMs [2]. The paper classified CMs into two categories (primary and secondary) based on the predominant organ involvement. Primary CMs (which include genetic, non-genetic or acquired) solely or predominantly affect the myocardium whereas secondary CMs exhibit pathological myocardial involvement as part of a larger number and variety of a generalized systemic (or multi-organ) disease. Whereas the AHA statement did not explicitly classify deposition diseases as a sub-category of CMs, listed amyloidosis and hemochromatosis among the leading causes of infiltrative and storage CMs respectively, which are sub-categories of secondary CMs [2]. Since then, deposition diseases have attracted a growing research attention as an important aetiology of CMs. However, data on deposition diseases CMs is sporadic, which has undermined a holistic understanding of the disease. However, with the current enhanced clinical awareness and better diagnostic imaging techniques, the incidence of deposition diseases in CM patients is increasing, which underscores the need for an understanding on the disease process as well as improving diagnostic and management strategies [3]. Thus, this review summarizes published evidence on the epidemiology, pathophysiology, clinical presentation, diagnosis and management including a meta-analysis of diagnostic and therapeutic strategies. This review also highlights grey areas of that would benefit from further research to improve the diagnosis and management of CMs secondary to deposition diseases.

Deposition diseases causing cardiomyopathies

Typical characteristic of deposition diseases is the accumulation of endogenous or exogenous substances on various body organs, which if left untreated may potentially lead to organ dysfunction and eventually death. Although numerous deposition diseases exist, few involve the heart and fewer result in CM. The most commonly encountered deposition diseases with pathological myocardial involvement include amyloidosis, hemochromatosis, oxalosis and ochronosis.

Cardiac amyloidosis

Amyloidosis is a degenerative protein-deposition disease in which a specific precursor protein pathologically misfolds from its physiological tertiary structure into a more linear shape dominated by unbranched beta-pleated sheet configuration [4]. These abnormally misfolded proteins aggregate into oligomers and eventually form insoluble amyloid fibrils (serum protein), which accumulate extracellularly in tissues. Both the circulating oligomers (which exert a cytotoxic effect) and the amyloid fibrils (which cause distortion of tissue architecture) lead to tissue dysfunction [4]. Whereas neurologic

*Correspondence to: Aref Albakri, St-Marien hospital Bonn Venusberg, Department of internal medicine, Bonn, Germany, E-mail: arefalbakri@yahoo.com

Key words: deposition diseases cardiomyopathy, dilated cardiomyopathy, cardiac amyloidosis, hemochromatosis, oxalosis, ochronosis

Received: June 12, 2019; Accepted: July 04, 2019; Published: July 08, 2019
amyloidosis such as Alzheimer’s and Parkinson’s diseases have received the greatest recognition, there are also a number of systemic amyloidoses affecting virtually all organs except the brain [5,6]. Clinical manifestations vary based on the site of amyloid deposits and the type of precursor protein involved [4].

Many types of precursor protein can affect the heart: (i) light-chain (LC) immunoglobulin; (ii) mutant hereditary transthyretin (TTR); (iii) wild-type TTR; (iv) mutant apolipoprotein; (v) amyloid atrial natriuretic peptide localized to the atrium; (vi) fibrinogen alpha type; and (vii) serum amyloid A (SAA) protein [7,8]. Secondary amyloidosis is typically a consequence of chronic inflammatory conditions such as rheumatoid arthritis, Crohn’s disease or other chronic inflammatory/infectious diseases or familial Mediterranean fever of idiopathic amyloid A amyloidosis [9,10]. Typical organs involved in amyloidosis are liver, kidney, gastrointestinal (GI) tract, nervous tissue and the heart. The presence of amyloid deposits in cardiac tissues varies with the type of amyloid disease (or precursor protein): systemic senile amyloidosis (SSA) and some forms of TTR-related amyloidosis (ATTR) that affect the heart almost invariably while cardiac involvement in amyloidosis light chain (ALC) occurs in about 50% of the cases. In secondary amyloidosis, cardiac involvement is rare, minimal or clinically non-significant [8]. Table 1 presents a list of the most common types of amyloidosis alongside their precursor protein, typical decade of presentation and organs involved.

### Types of cardiac amyloidosis

Light chain amyloidosis (AL): Amyloidosis light chain (AL), formally known as primary amyloidosis, is a clonal plasma cell disorder caused by the overproduction and misfolding of antibody light chain fragments. The disease is rare with about 3,000 new cases reported annually in the United States [12]. The median age of diagnosis is 63 years, although the disease can present in patients as early as the third or fourth decade of life [12,13]. The spectrum and pattern of organ involvement is very wide but cardiac involvement occurs in about half of the cases and sometimes it is the only presenting feature [14]. AL may progress rapidly. Low QRS voltages are common, particularly in the limb leads. Typically, thickening of the left ventricular (LV) wall is mild to moderate and rarely greater than 18 mm even in advanced disease. Cardiac AL amyloid deposits leads to a marked elevation of atrial natriuretic peptide localized to the atrium; (vi) fibrinogen alpha type; and (vii) serum amyloid A (SAA) protein [7,8]. Secondary amyloidosis is typically a consequence of chronic inflammatory conditions such as rheumatoid arthritis, Crohn’s disease or other chronic inflammatory/infectious diseases or familial Mediterranean fever of idiopathic amyloid A amyloidosis [9,10]. Typical organs involved in amyloidosis are liver, kidney, gastrointestinal (GI) tract, nervous tissue and the heart. The presence of amyloid deposits in cardiac tissues varies with the type of amyloid disease (or precursor protein): systemic senile amyloidosis (SSA) and some forms of TTR-related amyloidosis (ATTR) that affect the heart almost invariably while cardiac involvement in amyloidosis light chain (ALC) occurs in about 50% of the cases. In secondary amyloidosis, cardiac involvement is rare, minimal or clinically non-significant [8]. Table 1 presents a list of the most common types of amyloidosis alongside their precursor protein, typical decade of presentation and organs involved.

### Types of cardiac amyloidosis

Light chain amyloidosis (AL): Amyloidosis light chain (AL), formally known as primary amyloidosis, is a clonal plasma cell disorder caused by the overproduction and misfolding of antibody light chain fragments. The disease is rare with about 3,000 new cases reported annually in the United States [12]. The median age of diagnosis is 63 years, although the disease can present in patients as early as the third or fourth decade of life [12,13]. The spectrum and pattern of organ involvement is very wide but cardiac involvement occurs in about half of the cases and sometimes it is the only presenting feature [14]. AL may progress rapidly. Low QRS voltages are common, particularly in the limb leads. Typically, thickening of the left ventricular (LV) wall is mild to moderate and rarely greater than 18 mm even in advanced disease. Cardiac AL amyloid deposits leads to a marked elevation of atrial natriuretic peptide localized to the atrium; (vi) fibrinogen alpha type; and (vii) serum amyloid A (SAA) protein [7,8]. Secondary amyloidosis is typically a consequence of chronic inflammatory conditions such as rheumatoid arthritis, Crohn’s disease or other chronic inflammatory/infectious diseases or familial Mediterranean fever of idiopathic amyloid A amyloidosis [9,10]. Typical organs involved in amyloidosis are liver, kidney, gastrointestinal (GI) tract, nervous tissue and the heart. The presence of amyloid deposits in cardiac tissues varies with the type of amyloid disease (or precursor protein): systemic senile amyloidosis (SSA) and some forms of TTR-related amyloidosis (ATTR) that affect the heart almost invariably while cardiac involvement in amyloidosis light chain (ALC) occurs in about 50% of the cases. In secondary amyloidosis, cardiac involvement is rare, minimal or clinically non-significant [8]. Table 1 presents a list of the most common types of amyloidosis alongside their precursor protein, typical decade of presentation and organs involved.

### Table 1. Summary of pathology and presentation of different types of amyloidosis

<table>
<thead>
<tr>
<th>Amyloid Type</th>
<th>Precursor of Amyloid Fibril</th>
<th>Typical Decade of Presentation</th>
<th>Organs Involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>AL Immunoglobulin light chain</td>
<td>6th or 7th</td>
<td>Heart, kidney, liver</td>
<td></td>
</tr>
<tr>
<td>ATTR (V30M) Mutant TTR</td>
<td>3rd or 4th but varies geographically</td>
<td>Heart (uncommon), peripheral/ autonomic nerve</td>
<td></td>
</tr>
<tr>
<td>ATTR (T60 A) Mutant TTR</td>
<td>6th</td>
<td>Heart (up to 90%), peripheral/ autonomic nerve</td>
<td></td>
</tr>
<tr>
<td>Wild-Type ATTR Wild Type TTR</td>
<td>7th but may be considered after 5th</td>
<td>Heart, carpal tunnel syndrome</td>
<td></td>
</tr>
<tr>
<td>ATTR Ile 122 Mutant TTR</td>
<td>6th of older</td>
<td>Heart, carpal tunnel syndrome</td>
<td></td>
</tr>
<tr>
<td>Apolipoprotein Mutant apolipoprotein</td>
<td>6th or older</td>
<td>Heart (rare), predominantly Kidney</td>
<td></td>
</tr>
<tr>
<td>Secondary Amyloidosis Serum Amyloid A (SAA)</td>
<td>Any</td>
<td>Heart (rare), kidney, liver</td>
<td></td>
</tr>
<tr>
<td>Atrial Natriuretic Peptide (ANP)</td>
<td>7th or older</td>
<td>Heart</td>
<td></td>
</tr>
</tbody>
</table>

AL: Amyloidosis Light chain; ANP: Atrial Natriuretic Peptide; ATTR: Amyloidosis Transthyretin; TTR: Transthyretin; Tx: Transplantation; Adapted from Banypersad et al. [11].
ATTR may be indistinguishable from advanced AL, ATTR patients have fewer symptoms and better survival [27].

Pathophysiology: Both AL and ATTR-associated cardiac amyloidosis result in diffuse fibril deposition in the heart leading to the thickening of both ventricles [28,29]. The pattern of amyloid deposition in AL is usually sub-endocardial and diffuse while ATTR (especially ATTRc) can have patchy areas of transmural involvement. Phenotypic expression may vary in particular in ATTR, where a subset may exhibit asymptomatic septal hypertrophy mimicking hypertrophic cardiomyopathy (HCM) [30-32]. In cardiac amyloidosis, amyloid deposits occur extracellularly in the interstitium, surrounding the myocytes although there may be depositions in the small intramural coronary arteries. In contrast, in sarcoidosis, amyloid depositions can occur throughout the myocardial tissue. Thus, endomyocardial biopsy is nearly 100% sensitive for the diagnosis of cardiac amyloidosis [33-36].

In some cases, the atria may be involved with inter-atrial septal thickening resulting in poor atrial function and increased rates of atrial fibrillation (AF) as well as the conduction system leading to various degree of heart block and bundle branch block, which manifest more frequently in ATTR than in AL [29,37,38]. The valves usually thicken accompanied by mild to moderate regurgitation. The involvement of pericardial may lead to small pericardial effusions and coronary involvement of the small intramural vessels may lead to ischemia and angina with normal epicardial coronaries that are more common in AL than in ATTR [8,39,40]. Thickened bi-ventricular walls result in a non-dilated ventricle that is stiff and poorly compliant leading to progressive abnormalities in diastolic filling. Systolic dysfunction may be observed in severe and advanced disease. However, LV ejection fraction (LVEF) on echocardiography may be less reliable since reduced end-diastolic volume produces a low stroke volume. For example, LVEF of 50% when starting at a significantly reduced end-diastolic volume (e.g. 70 mL), leads to a significantly reduced stroke volume (35 mL) and thus reduced cardiac output. This may explain why patients with cardiac amyloidosis cannot tolerate reduced heart rates since cardiac output depends on the heart rate [41-43].

Clinical presentation: Irrespective of the precursor protein and disease type, cardiac amyloidosis may present as a restrictive cardiomyopathy (RCM) characterized by progressive diastolic and subsequently systolic biventricular dysfunction and arrhythmia [8]. Typical presentation of cardiac amyloidosis is HF with preserved ejection fraction (HFpEF). Exertional dyspnea is common although some patients may present with a more right-sided HF symptoms such as lower extremity oedema and ascites. Patients may present with fatigue and weakness associated with low cardiac output and often linked to non-specific symptoms of ageing. Patients with thickened ventricles may be misdiagnosed as having HCM with or without obstruction [41,60]. The initial manifestation of cardiac amyloidosis may be AF (mostly in ATTRc) or cardioembolic stroke. AF can be present for years before the diagnosis of cardiac amyloidosis is made. Bundle branch block and complete heart block (mostly in ATTR than in AL patients) may require pacemaker implantation. Angina with normal coronary artery can occur while cardiogenic shock due to diffuse ischemia is a rare occurrence [8,39,40]. Elderly patients may present with low-flow, low-gradient aortic stenosis [61].

Extra cardiac involvement such as nephrotic syndrome, autonomic neuropathy, pulmonary or bronchial involvement particularly in AL might cloud cardiac presentation. Pulmonary oedema is uncommon early in the disease process but pleural and pericardial effusion, and atrial arhythmia are frequent observations. [44-46]. Syncope is a common presentation and a poor marker of prognosis [47]. It is typically exertional or postprandial as part of RCM, sensitive to intravascular fluid depletion from loop diuretics in combination with autonomic neuropathy or conduction tissue involvement (atrioventricular or sinoatrial nodes) or ventricular arrhythmia [48-50]. Disproportionate sepal amyloid accumulation mimicking HCM with dynamic LV outflow tract obstruction is rare but well documented [51-54]. Myocardial ischemia may result from amyloid deposits within the microvasculature [55,56]. Atrial thrombus is a common occurrence particularly in AL patients sometimes occurring before AF [57]. Intracardiac thrombus may embolize, causing transient ischemic attacks or strokes and may be an early or even the presenting feature [58]. Anticoagulation is therefore important in the appropriate clinical situation but careful consideration should be given to patients with extensive systemic AL who may have elevated haemorrhaging risk due to factor X deficiency or in some cases with GI involvement [59].

Several other symptoms can help raise clinical suspicion of cardiac amyloidosis (Table 2). Bilateral carpal tunnel syndrome is a common presentation in both AL and ATTR but more so in ATTRc and can precede clinical HF by several years [21,24,60]. Spinal stenosis is specific to ATTR patients due to amyloid infiltration of the ligamentum flavum [22]. In previously hypertensive patients, low to normal blood pressure leading to discontinuation or reduction of anti-hypertensive therapy may suggest possible cardiac amyloidosis. Peripheral and autonomic neuropathy may occur in both AL and ATTR but uncommon in ATTRc [23]. Other clinical signs and symptoms of AL can include macroglossia and periorbital purpura, proteinuria, jaw claudication and GI symptoms of diarrhoea and weight loss [60].

Clinical evaluation: Clinical evaluation of cardiac amyloidosis involves three features: (i) demonstration of amyloid protein in tissue specimen; (ii) identification of affected organs; and (iii) definition and type of amyloidosis [3]. According to the AHA 2016, cardiac amyloidosis is clinically suspected on echocardiography, usually performed because of the presence of HF symptoms or for screening purposes when the diagnosis of amyloidosis has been established in extra cardiac organs. Typical echocardiography features of cardiac amyloidosis include thickened bi-ventricular walls in the setting of

Table 2. Symptoms raising clinical suspicion of amyloidosis cardiomyopathy

<table>
<thead>
<tr>
<th>Common Clinical Symptoms of Cardiac Amyloidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>On echocardiography:</td>
</tr>
<tr>
<td>• Low voltage on ECG + thickening of septum/posterior wall &gt; 1.2 cm</td>
</tr>
<tr>
<td>• Thickening of RV free wall and valves</td>
</tr>
<tr>
<td>• Intolerance to beta-blockers or ACE-inhibitors</td>
</tr>
<tr>
<td>Low normal BP in patients with a previous history of hypertension</td>
</tr>
<tr>
<td>History of bilateral carpal tunnel syndrome, often requiring surgery</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Light Chain Amyloidosis (AL)</th>
<th>Transthyretin Amyloidosis (ATTR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HF + Nephrotic Syndrome</td>
<td>White male age ≥ with HFpEF + history of carpal tunnel syndrome and/or spinal stenosis</td>
</tr>
<tr>
<td>Macroglcosia and/or peribetal purpura</td>
<td>African American age ≥ 60 with HFpEF without a history of hypertension</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>New diagnosis of hypertrophic cardiomyopathy in elderly patient</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>New diagnosis of low flow, low gradient aortic stenosis in elderly patient</td>
</tr>
<tr>
<td>Monoclonal gammopathy of undetermined significance</td>
<td>Family history of ATTR amyloidosis</td>
</tr>
</tbody>
</table>

ACE: Angiotensin-Converting Enzymes; AL: Light Chain Amyloidosis; ATTR: Transthyretin Amyloidosis; BP: Blood Pressure; ECG: Electrocardiogram; HF: Heart Failure; HFpEF: Heart Failure with Preserved Ejection Fraction; RV: Right Ventricular
normal ventricular size, bi-atrial dilation, the presence of pericardial effusion, and valvular thickening without significant dysfunction. Increased echogenicity of the myocardium is non-sensitive when considered in isolation but should raise clinical awareness in the presence of typical findings listed previously although it has become less discernible in newer echocardiographic modalities. Thickened ventricular walls in the absence of known causes such as hypertension or aortic stenosis raises the clinical suspicion for an infiltrative disease process. Doppler studies demonstrate impaired LV relaxation and restrictive filling pattern. Initially, LV systolic function may be preserved but it gradually declines as the disease progresses [11,62,63]. On ECG, low QRS voltage amplitude occurs in approximately 50% of patients with cardiac amyloidosis despite the presence of thickened ventricular wall on cardiac imaging. Other common ECG abnormalities include a pseudoinfarct pattern in the precordial leads, AF, and atrioventricular (AV) conduction abnormalities [3].

Nuclear imaging with technetium pyrophosphate has been shown to be insensitive. However, if uptake is present, amyloid infiltration should be considered, depending on the clinical setting, and may be useful in distinguishing between AL and ATTR [64,65]. Cardiac MRI shows a characteristic late gadolinium enhancement (LGE) pattern that is diffuse and sub-endocardial that does not follow any particular coronary distribution. LGE can also be seen in the RV and the atrial walls, and can be transmural and patchy in ATTR [4]. However, the accuracy and utility of cardiac MRI in the diagnosis of cardiac amyloidosis remains uncertain although it could help identify the extent of cardiac involvement in patients with an established diagnosis of amyloidosis [66,67]. BNP levels may also be helpful in the diagnosis and follow-up of cardiac amyloidosis patients. Elevated BNP levels have been observed even in the absence of clinical evidence of clinical HF or increased wall stress suggesting it might be caused by elevated ventricular filling pressure and by direct myocyte damage due to extracellular amyloid deposits. Elevated BNP suggest cardiac involvement with sensitivity and specificity of 93% and 90% respectively [68,69]. Elevated BNP may also be helpful to predict the development of clinical cardiac involvement in the future [70]. BNP levels decrease with chemotherapy of AL possibly suggesting organ response [71].

Diagnostic gold standard for cardiac amyloidosis is histologically from endomyocardial biopsies (EMB) of abdominal fat pad, gingiva, rectum, bone marrow or other affected organs such as heart, liver and kidney. However, its main limitations are it has 1% risk of ventricular perforation leading to cardiac tamponade and it is usually unavailable in many centres [4]. Other definitive diagnosis for cardiac amyloidosis include light microscopy showing amorphous pink deposits in the interstitium. With Congo red staining, amyloid fibrils produce apple-green birefringence under polarized microscopy. Other confirmative test is electron microscopy and proteomic typing by mass spectrometry [72,73]. EMB that identifies amyloid protein provides the definitive diagnosis of cardiac amyloidosis. In patients with extra-cardiac tissue-proven systemic amyloidosis, echocardiographic or cardiac MRI findings suggestive of infiltrative CM (such as wall thickness > 12 mm) can support the diagnosis of cardiac amyloidosis obviating the need for EMB [74].

After establishing the diagnosis of cardiac amyloidosis, the next diagnostic step is to identify the type of amyloidosis, which is instrumental in determining both treatment strategy and prognostication. Immunohistochemistry can be performed on tissue samples with antibodies against amyloid A, light chains and TTR amyloid [62]. If TTR is detected, DNA mutational analysis can help distinguish between senile and hereditary amyloidosis [73]. The presence of serum or urine monoclonal gammapathy suggests the presence of AK amyloidosis but does not establish the diagnosis. In reactive (AA) amyloidosis, deposited protein is serum amyloid protein A, an acute phase protein that is normally soluble and whose plasma concentration is the highest during inflammation. AA amyloidosis is a complication of a number of inflammatory diseases and infections including tuberculosis, chronic osteomyelitis and autoimmune diseases. AA amyloid deposits are primarily in the liver, spleen and kidney and rarely affect the heart [3].

Clinical management: Generally, cardiac amyloidosis has a poor prognosis, which differs based on amyloid type, and availability and response to therapy. Treatment for the most part is supportive therapy – modified HF treatment including device therapy. Other treatment options include therapies that suppress the production of amyloid fibril precursor protein such as chemotherapy in AL amyloidosis, and novel strategies to inhibit amyloid fibril formation or directly targeting amyloid deposits or stabilize the precursor protein especially ATTR. Cardiac transplantation, although not in common use, can very successful in carefully selected patients [3,11].

Supportive treatment includes standard HF therapy. This may be of limited benefit or even detrimental in cardiac amyloidosis, which requires careful monitoring to avoid significant drug interactions and adverse side effects [76]. The evidence for the use of angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs) or beta-blockers. Toleration for HF medication may be poor and may aggravate postural hypotension or renal function. Some patients may develop BCM leading to heart rate dependent cardiac output and these patients may find it difficult tolerating beta-blockers. Digitalis and calcium channel blockers may be selectively concentrated in amyloidotic tissue and may be relatively contraindicated because of increased toxicity [76-78]. The maintenance of adequate filling pressure is crucial because of restrictive physiology, balancing peripheral oedema and renal impairment with salt/water restriction and judicious use of diuretics. Patient education and participation with conjunction with HF team is critical to successful manager. Maintenance of adequate BP with an alpha-antagonist (such as midodrine) may permit higher doses of loop diuretics, especially in patients with autonomic neuropathy [79]. Device therapies such as pacemakers or implantable cardioverter defibrillators (ICD) may not prevent sudden cardiac death due to electromechanical dissociation [80]. In the absence of evidence, pacing indications remain within the current standard guidelines. Biventricular pacing appear to have little role but although may be the ideal pacing option to avoid decompensation of the stiffened ventricles due to induced dys synchrony from RV pacing [81].

Amyloid specific treatment includes reducing the production of amyloid fibril precursor-protein or inhibition of amyloid formation [11]. In AL patients, treatment for reducing the supply of amyloid-fibril precursor protein targets the clonal plasma cells using cyclical combination chemotherapy or high dose therapy with autologous stem cell transplantation. Most chemotherapy regimens consist of dexamethasone together with alkylator. However, the use of dexamethasone should be cautious because of the risk of fluid overload in the absence of adequate and rapid changes to diuretic therapy requiring close coordination between teams treating haematology and cardiology to improve outcomes [82]. High-dose melphalan followed by autologous stem-cell transplantation is generally contraindicated in patients with advanced cardiac amyloidosis although autologous stem cell transplantation may be the best treatment for suitable patients [83-85].
Besides AL, AA amyloidosis is the only other type in which available therapies can effectively suppress the production of fibril precursor. Anti-inflammatory therapies such as anti-tumour necrosis factor agents in rheumatoid arthritis can significantly suppress the production of serum amyloid A protein although with limited clarity on the effect on cardiac involvement, which is very rare in AA amyloidosis. Since the liver almost exclusively produces TTR, ATTR has become a focus of novel drug developments to suppress TTR production through silencing RNA and antisenese oligonucleotide therapies [86]. Finally, the concept of treatment by inhibiting amyloid formation is based on the observations that amyloid fibril formation involves conformational transformation of precursor proteins into a completely different form with predominant beta-sheet structure. This conversion may be inhibited by stabilizing the fibril precursor through specific binding to a pharmaceutical has been explored in ATTR with promising results [87,88]. Finally, following treatment that prevents production of new amyloid, treatment that targets amyloid deposits by immunotherapy may mobilize AL deposits in a majority of patients. However, cardiac clearance of amyloid is slow and echocardiographic evidence of improvement has not been confirmed. The concept of passive immunotherapy to enhance clearance has proved successful in experimental models and is currently in clinical development [11].

**Haemochromatosis:** Haemochromatosis is an autosomal recessive disorder associated with abnormal deposition of iron in parenchymal organs causing organ toxicity and dysfunction or primary iron-overload CM [89,90]. The disease is almost exclusive to populations of Northern Europe descent [91]. Primary iron-overload CM was first described in the 18th Century characterized by a clinical triad of cirrhosis, hyperpigmentation of the skin and diabetes presented in about 15% of the patients [90]. In the 19th Century it was recognized that haemochromatosis is hereditary in nature and occurs due to mutations in the genes encoding proteins involved in iron metabolism [92,93].

**Types of Haemochromatosis**

Haemochromatosis has four sub-types caused by increased GI absorption of iron into the bloodstream and reduced activity or synthesis of hepcidin protein that regulates the entry of iron into circulation [94,95]. Type 1 is due to mutations of the HFE gene on chromosome 6 that accounts for more than 80% of cases of haemochromatosis and corresponds to classical hereditary haemochromatosis. Type 2: is due to mutations of the HJV gene on chromosome 1 that encodes hepcidin (subtype 1A) or in the HAMP gene on chromosome 19 that encodes hepcidin (subtype 2B). Type 3 is due to mutations of the TFR2 gene on chromosome 7 encoding transferrin receptor 2. Finally, Type 4 is due to mutations of the SLC40A1 gene on chromosome 2 that encodes ferroportin. All these mutations are inherited in an autosomal recessive pattern with the exception of Type 4, which is inherited in an autosomal dominant pattern [94]. Types 1, 3 and 4 present in adulthood and usually during the fourth or fifth decade of life while Type 2 (also known as juvenile haemochromatosis) presents much earlier in the second or third decades of life and its phenotype is much more severe [93]. The classical triad of haemochromatosis (cirrhosis, bronze skin and diabetes mellitus) but it is extremely variable and depends on several interfering genetic and non-genetic factors especially in Type 1. In Types 1 and 3, hepatic involvement predominated while in Type 2, endocrine and cardiac complications predominate and HF is a frequent cause of death before the third decade of life [93].

**Pathophysiology:** In haemochromatosis, inappropriately high duodenal iron absorption compared with the total body iron content leads to iron overload [96]. During iron overload, transferrin (iron-binding blood plasma glycoproteins that controls the level of iron in biological fluids), which is normally about 30% saturated, becomes fully saturated leading to the appearance of the toxic non-transferrin-bound iron species in the circulation [97]. The negative feedback mechanisms that regulates transferrin bound iron uptake does not control cellular uptake of non-transferrin-bound iron together with the lack of an iron excretory mechanism leads to intracellular iron accumulation. The uptake of iron from non-transferrin-bound iron species in hepatocytes, cardiomyocytes and endocrine gland cells results in tissue iron accumulation and ultimately the deleterious effects of iron overload [98]. During iron overload, iron in the form of ferrous iron (Fe^{2+}) diffuses into the cardiomyocytes via the voltage-dependent L-type calcium channels [99]. Myocardial iron overload occurs later than hepatic iron overload due to slower myocardial iron uptake. Initially, iron accumulates in the ventricular myocardium then in the atria myocardium as well as affects the conducting system but to a lesser extent relative to the myocardium [97]. The epidermis has a higher iron concentration than the sub-endocardium but the difference becomes blurred in severe iron overload CM [100]. Pathological iron deposition begins initially within the epidermis then extends to the myocardium and then endocardium, which explains the preservation of systolic function until very late in the disease process [95].

The cardiomyocytes stores iron in the form of ferritin (the primary site of iron storage), hemosiderin and labile cellular (free) iron. Labile iron leads to the formation of reactive oxygen species (ROS) through the Fenton reaction that converts ferrous to ferric iron with the generation of the toxic hydroxyl radical [94]. Once the cellular antioxidant capacity is exceeded, the rapid Fenton reaction catalyses iron to produce hydroxyl iron (an extremely free radical species), which causes lipid peroxidation producing membrane permeability alterations. These modifications create a leak of hydrolytic enzymes that initiate cell damage and subsequently cardiomyocyte death. In the presence of myocardial ischemia, iron overload can accelerate ischemia-induced reperfusion injury and may lead to an autocatalytic process resulting in a cardiomyopathic process [101,102]. In addition, increased ferrous iron transportation via the L-type calcium channels may cause derangement of cardiomyocyte calcium transportation and impaired excitation-contraction coupling, which in turn may contribute to the development of diastolic and systolic ventricular dysfunction association with iron-overload CM [103]. The end-result of the previously described processes is the development of CM characterized mainly by LV dysfunction [104,105]. In addition to direct myocardial injury, iron overload may exert an indirect effect on the myocardium via its effect on other organs. Hepatic dysfunction, endocrinopathies (diabetes mellitus, hypo- and hyper-thyroidism, hypo-parathyroidism), and immune deficiency all due to iron overload contribute to the pathophysiology of iron overload CM [106,107]. Besides iron overload, other mechanisms such as immune-inflammatory and genetic factors appear to interfere in the pathogenesis of iron overload Cx such as myocarditis, the HLA genotype and the apolipoprotein E genotype [100,105,108].

Iron overload CM presents in two phenotypes, dilated and restrictive. The dilated phenotype results from a process of LV remodelling leading to chamber dilatation and depressed LVEF while the restrictive phenotype results from diastolic dysfunction with restrictive filling, preserved LVEF, pulmonary hypertension and subsequent RV dilatation [104]. In addition to these typical manifestations, two phenotypes may be followed by several other manifestation including conduction system abnormalities,
tachyarrhythmias and perimyocarditis [109-111]. In the early stages of iron overload CM, myocardial iron overload manifests as diastolic LV dysfunction with elevated LV filling pressures [112,113]. If the cause of iron overload persists with no appropriate treatment, a majority of patients go on to develop LV remodelling ultimately leading to LV dilatation and depressed LVEF (the dilated phenotype) [104,114]. In fewer than 10% of older patients with severe iron overload, restrictive LV dysfunction leads to pulmonary hypertension, RV dilatation and right-sided HF without LV anatomic remodelling with preserved LVEF (restrictive phenotype) [114,115]. The development of dilated or restrictive phenotype depends on the interaction between the main disease and additional immuno-inflammatory and molecular factors such as myocarditis (dilated phenotype) [94].

**Clinical presentation:** Patients with iron-overload CM often are asymptomatic in the early stages of the disease. Excessive or chronic iron overload may result into irreversible HF if not detected early; thus, early identification is very important to improve the efficacy of clinical management [89]. Once HF develops, there is a marked deterioration. Cardiac haemochromatosis may result into DCM with dilated ventricles, low LVEF and low fractional shortening [116,117]. Initially, patients may experience exertional dyspnoea due to LV diastolic dysfunction with restrictive hemodynamics and increased filling pressures (restrictive phenotype). The dilated phenotype with depressed LVEF develops as the disease progresses. Bi-ventricular failure may ensue causing pulmonary congestion, peripheral oedema and hepatic congestion [118]. Pericardial constrictive or tamponade due to pericardial iron accumulation may lead to rapid clinical deterioration [119]. Angina pectoris in the absence of coronary artery disease responding to venesecion may also manifest [120]. Excessive deposition of iron in the entire cardiac conduction system, particularly the AV node, may occur. Complete AV block due to iron deposition may require permanent pacemaker therapy [121]. Iron deposition in cardiac tissues may also lead to non-homogenous electrical conduction and repolarization accompanied with atrial and ventricular tachyarrhythmias [122]. Persistent iron overload causes a reduction in calcium-dependent L-type Ca**+** current causing bradycardia, altered electrical conduction and AF [123]. Paroxysmal AF is the most common arrhythmia seen in patients with cardiac haemochromatosis. The prevalence of ventricular arrhythmias correlates with LV dilatation and depressed LVEF. Sudden cardiac death may develop in some patients [124]. However, there is no association between cardiac haemochromatosis and ischemic heart disease or myocardial dysfunction [125,126].

**Clinical evaluation:** A high index of suspicion is necessary to identify and categorize iron overload CM secondary to haemochromatosis. Diagnosis can be very challenging in the early stages of the disease. Accurate assessment of organ specific iron overload will be helpful [95]. According to AHA diagnostic statement on DCM, upon clinical suspicion, the diagnosis of haemochromatosis associated iron overload CM begins with biochemical markers (serological testing) and includes investigation of end-organ involvement, followed by transthoracic echocardiography with complete LV diastolic function assessment including tissue velocity measurements of the mitral annulus, and finally cardiac MRI to confirm or exclude myocardial iron overload [3].

Serum transferrin saturation – serum iron/total iron bonding capacity of >45% and elevated serum ferritin > 200 µg/L in men or 150 µg/L in women supports diagnosis according to the AHA guidelines for specific forms of DCM [3] and the American College of Physicians (ACP) guidelines for hereditary hemochromatosis [127,128]. However, serum iron studies poorly correlate with disease severity and uncertain in some patient populations. Transferrin saturation can miss a significant population of patients homozygous for HFE mutations [129]. It may also be elevated along with ferritin levels in Asian and pacific Islanders without HFE mutations and thus have uncertain significance in these populations [130]. Upon suspicion for hereditary haemochromatosis especially with a known family history of haemochromatosis, testing for the haemochromatosis genotype should be performed [3].

Diagnosis of cardiac dysfunction may be possible with echocardiography. As iron overload proceeds, echocardiography may show biventricular dilatation and progressive evidence of RCM from myocardial damage [131]. Echocardiographic evidence of ventricular diastolic dysfunction can detected early before systolic dysfunction by tissue Doppler signals [132,133]. Diagnosis of cardiac iron overload is possible with cardiac MR (the only non-invasive modality that can assess quantitatively myocardial iron load) in which decreased T2 signal correlates with myocardial iron-infiltration and depressed LV function. Cardiac MRI is useful in identifying when therapy is indicated and serial imaging can measure response to medical therapy [3]. The traditional gold standard for making the diagnosis of liver iron overload is tissue biopsy but iron deposit in the heart can be patchy [134]. Thus, tissue biopsy may miss the areas of deposition and provide a false negative result.

**Clinical management:** Generally, the treatment for iron overload states targets the prevention or reversal of cardiac dysfunction [136-139]. Removal of excess iron from the tissues in these patients minimizes the generation of free radicals to minimize organ damage [140,141]. The established treatment for haemochromatosis is phlebotomy and chelation therapy for secondary iron overload. Clinical therapy recommendations are well outlined in the American Association for the study of liver diseases haemochromatosis practice guidelines [142]. Therapeutic phlebotomy is started with serum ferritin levels ≥ 300 µg/L in men and ≥ 200 µg/L in women irrespective of the presence or absence of symptoms [139]. Therapeutic phlebotomy consists of removing one (1) unit of blood (450-500 ml) weekly until the serum ferritin level is 10 to 30 µg/L and maintenance of serum ferritin level ≤ 50 µg/L after periodic blood removal [139]. Each unit of blood removed depletes 200 to 250 mg of iron from the blood, which then mobilizes an equal amount of iron stored in the tissues to form haemoglobin [143]. However, patients with ferroportin mutation associated iron overload may not tolerate a more aggressive therapy [144].

In addition to phlebotomy, dietary management should be included in the therapy. Avoidance of medicinal iron and iron supplements [139]. Eating large amounts of vitamin C rapidly mobilizes iron from the heart, increases free radicals production and causes life-threatening cardiac arrhythmias [145,146]. Thus, supplemental vitamin C should avoided although vegetables and fruits rich in vitamin C may be ingested [147]. Alcohol increases iron absorption and some red wines contain high iron content [148,149] and both should be avoided. Seafood such as uncooked shellfish should be avoided [149]. Patients with CM and HF should be treated with a low sodium diet [150]. Haemochromatosis patients with HF should be managed with standard medical therapy for HF as per the current HF guidelines [150]. Cardiac transplantation is a therapeutic option for haemochromatosis patients with HF refractory to optimal medical therapy and cardiac resynchronization therapy [150-152].
Oxalosis

The initial description of the deposition of calcium oxalate crystals in human tissues was made in 1935 in the kidney of a 4.5 years old child who had multiple urethral, ureteric and bilateral renal calculi [153]. Chou and Donohue [154] coined the term “oxalosis” in 1952 to describe the clinical condition in which calcium oxalate crystals deposits in the kidney, and later Scowen et al. [155] used the term for cases with disseminated extra-renal calcium oxalate depositions. The present definition of oxalosis is a rare metabolic disorder characterized by the inability of kidneys to eliminate calcium oxalate crystals through the urine or enhanced production of oxalic acid leading to hyperoxalemia and a deposition of calcium oxalate in different body organs [156,157]. Oxalate is a by-product of normal metabolism. It is produced endogenously as an end-product of the metabolism of amino acids and absorbed by the stomach, small bowel and colon from dietary sources [158]. In healthy individuals, up to a half of urinary oxalate is derived from dietary sources. Oxalate can be excreted dissolved in urine, precipitated with calcium in the stool or metabolized by gut microbiota [158]. Under normal conditions, all oxalate absorbed from dietary sources is excreted through the urine. Normal urinary oxalate excretion is variable but a value of 40–45 mg/day (0.45 mmol)) is considered hyperoxaluria [159]. Calcium oxalate deposits on the myocardium or the conduction system can potentially lead to life-threatening arrhythmias, CM, and HF. The frequency and severity of cardiac oxalosis remain poorly described with the lack of organized data beyond sporadic literature reports. Current information is limited case reports and small case series, which are restricted to CM, valvular diseases and conduction abnormalities [161].

Types of Oxalosis: Oxalosis can be classified into two types: (i) primary oxalosis; and (ii) secondary oxalosis. Primary oxalosis results from hyperoxaluria, described as an inborn error of metabolism transmitted in an autosomal recessive fashion in which the liver cannot create enzyme peroxisomal alanine-glyoxylate aminotransferase or the enzyme does not work properly [160,161]. The enzyme is responsible for regulating the production of oxalate. Its deficiency leads to an increase in the production of oxalate causing excessive amounts to be excreted in urine causing recurrent urolithiasis and nephrocalcinosis. The urinary daily excretion of calcium oxalate is raised constantly above the maximum normal of 40 mg [162]. In the urine, oxalate combines with calcium to form insoluble calcium oxalate crystals (kidney stones) that often damage the kidneys resulting in kidney failure. As progressive renal insufficiency occurs, reduced urinary oxalate excretion in turn results in marked increases in plasma oxalate concentrations and the consequence of systemic calcium oxalate deposition mainly in the muscoskeletal, cardiovascular and peripheral nervous systems, causing systemic oxalosis [157,161]. If left untreated, oxalis can potentially lead to death [160,161].

Secondary (also enteric) oxalosis on the other hand results from several factors including the interaction with environmental factors, underlying primary diseases or organ failure in patients with no personal or family history of oxalosis. The main secondary causes include: (i) dietary hyperoxaluria; (ii) enteric hyperoxaluria; or (iii) kidney failure. Dietary hyperoxaluria usually is the consequence of the consumption of foods high in oxalate content (ascorbic acid [vitamin C], ethylene glycol, xylitol and methoxylflurane), which can increase the levels of oxalate in urine and increase the risk of the formation of calcium oxalate crystals [163]. Enteric hyperoxaluria occurs as a result of certain intestinal diseases such as Crohn’s disease and Short Bowel Syndrome that can cause an increase in the absorption of oxalate from foods, thereby increasing the amounts of oxalate excreted in the urine [159]. Finally, kidney failure due to reasons other than hyperoxaluria in which oxalate can no longer be excreted from the body, can lead to oxalosis [159,161].

Pathological features: The primary route of oxalate elimination is via glomerular filtration. Thus, kidney dysfunction is the most common manifestation of oxalosis. Although cardiac involvement is uncommon, it is a major source of mortality in patients. Data on oxalosis with cardiac involvement is lacking and sporadic reports in literature are insufficient to paint an exact picture of the pathogenic mechanisms. In fact, recent guidelines on myocardial disease from both the AHA and ESC do not include calcium oxalate as a cause of CM [164,165]. Despite the lack of data, studies on patients with hyperoxaluria may provide insightful account of cardiac abnormalities in patients with oxalosis. In particular, a recent retrospective review of an institutional database for 103 patients with hyperoxaluria between 1948 and 2006 revealed several important cardiac abnormalities associated with calcium oxalate deposits on the myocardium [161].

In patients with oxalosis, critical plasma concentration for calcium oxalate of 30–45/μmol/L is easily exceeded as a result of compromised renal function and subsequent extra-renal oxalate deposition [166–168]. Increased calcium oxalate deposits on cardiac tissues has been associated with increased LV mass index (LVMI), impaired LV and RV function, diastolic function, left atrium enlargement, increased wall thickness suggesting myocardial infiltration and rhythm abnormalities. Hormonal and metabolic abnormalities associated with end-stage renal disease may lead to pulmonary vascular abnormalities resulting in pulmonary hypertension. Numerous case reports and limited case series describe calcium oxalate deposits on the myocardium leading to increased wall thickness, restrictive CM, HF, tricuspid and mitral regurgitation, conduction defects ventricular tachycardia, impaired bi-ventricular function [160,162,169-176]. Co-morbid renal failure and hypertension in oxalosis patients may also affect cardiac thickness and diastolic function. Cardiac histopathology analyses describe calcium oxalate deposition within the conduction system, the small intra-myocardial vessels and myocardium [157]. Conduction system abnormalities tachyarrhythmias, bradyarrhythmia, and CM. Secondary inflammatory response to oxalate deposits may also induce thickening and degeneration of collagen fibres, fatty infiltration, mononuclear cell infiltration and frank fibrosis [157,177].

For a better understanding of the pathophysiology of oxalosis CM, there is need for further prospective trials enrolling a large sample of oxalosis to determine or clarify the following concerns. (i) The time between diagnosis of oxalosis and the onset of cardiac manifestations. (ii) Plasma cut-off values for cardiac oxalate deposition associated with cardiac manifestations. (iii) Echocardiographic modalities that have greater sensitivity and specificity in diagnosis of cardiac abnormalities in oxalosis patients such as vector velocity imaging and strain of the LV and RV. (iii) Diagnostic role of cardiac computed tomography or cardiac MRI in providing additional information and evidence of vascular involvement that should obviate the need for myocardial biopsy, the current diagnostic gold standard. (iv) Dose-response of calcium oxalate deposition with higher plasma levels of oxalate causing higher levels of cardiac dysfunction, and whether, liver and kidney transplant may result into the regression of oxalate deposition, which is consistent with other deposition diseases such as haemochromatosis and cardiac amyloidosis.

Clinical evaluation: Oxalosis can present with a multitude of symptoms depending on the location of oxalate deposition, severity
and progression of the condition. Clinical presentation of oxalosis patients with cardiac involvement varies widely depending on the type and stage of the disease. They may present with atypical chest pain, exertional dyspnea, a history of hypertension, elevated plasma oxalate (43.4 µmol/L), decreased renal function with increased serum creatinine (3.39 mg/dl), and reduced glomerular filtration rate (72.3 ml/min) but with a normal mean blood pressure [161]. There are no expert consensus guidelines for the diagnosis and management of oxalosis CM. However, limited data based on findings of case reports and case series reveal that diagnosis may include a combination of tests such as serum tests for oxalate concentration, ECG and non-invasive imaging. ECG may demonstrate sinus tachycardia with atrioventricular sequential pacing [160], AV block progressing into a complete heart block [162]. Transthoracic echocardiography reveals mildly dilated LV with moderate severe systolic function, marked concentric thickening of both the LV and RV with patchy echodense speckled reflections in the myocardium, moderate pericardial effusion with no signs of cardiac tamponade, moderate tricuspid regurgitation [160]. Coronary angiography reveals high-grade stenosis but uncommon while chest x-ray reveals increased cardiothoracic ratio, pulmonary venous congestion (or hypertension) and bilateral pleural effusion [160,161]. These findings are sporadic based on case reports with no randomized controlled trials to confirm these diagnostic features.

Clinical management: Clinical management of oxalosis CM lacks established guidelines and well-defined treatment strategies. Current treatment strategies based on outcomes from case reports suggest treatment with vitamins and minerals can help to reduce or prevent oxalate accumulation in the body. Vitamin B6 can reduce oxalate excreted in the urine and oral preparations of phosphates and citrate can be useful in preventing oxalate crystals from developing. Other medications such as thiazide diuretics may be necessary contingent upon abnormalities in the urine [177]. For oxalosis CM due to primary hyperoxaluria, prescription doses of pyridoxine have been shown to decrease urine oxalate levels by approximately 30% [178]. Urine oxalate levels in individuals on pyridoxine should be monitored monthly to assess individual patient’s responsiveness to this drug. Symptoms related to oxalosis-induced oxalate arthritis have been described to be alleviated via the use of NSAIDs, colchicine and steroids.

Alkalization of urine with alkali citrate can reduce urinary calcium oxalate saturation by forming complexes with calcium thus reducing calcium oxalate crystals or nephrocalcinosis [178]. Dietary changes (limiting or eliminating foods high in oxalate from the diet) may be effective in reducing the amount of oxalate excreted in urine in patients in whom accumulation of oxalate is due to dietary causes [177]. If kidney function is not impaired, increasing fluid intake (>3 L/m² per day distributed throughout the day) will help to flush the kidneys and prevent oxalate build up and the formation of calcium oxalate crystals [178]. Dialysis is a temporary procedure used to compensate for kidney failure by imitating kidney function by removing extra fluids and toxins from the blood but cannot remove oxalate that accumulates elsewhere in the body [156,177]. For patients with kidney failure, a kidney and liver transplant may be necessary although there are cases of persistent echocardiographic abnormalities 12 months after transplant [156].

Ochronosis

Prevalence: Ochronosis (also alkaptonuric) is a very rare autosomal metabolic disorder caused by the deficiency of homogentisic acid (HGA) oxidase (alkaptonuria) affecting between 1 in 250,000 and 1 in 1 million births [179]. The highest incidence occurs in Slovakia and the Dominican Republic, where the incidence reached 1 in 19,000 births. It is a consequence of a discrete mutation in chromosome 3q21-3q23, leading to a deficiency in the homogentisate 1,2 dioxygenase (HGO) [180]. The deficiency of the enzyme (HGO) leads to an increase in the levels of HGA (a by-product of tyrosine and phenylalanine metabolism), accumulates and become polymerized and be systematically deposited within various tissues of the body (ochronosis) [181]. In the urine, the HGA is oxidized to a melanin-like material causing the urine to acquire a blackened appearance when exposed to air or reducing agents. In the body, the HGA undergoes polymerization causing it to accumulate in connective tissues, which appear ochre-coloured (yellow/brown) material under microscope [182,183]. As the disease progresses, tissue deposition of polymerized HGA eventually will lead to the progressive degeneration of all affected body systems. Although the term ochronosis has been applied to alkaptonuria, it also refers more generally to any deposition of an ochre-coloured material in connective tissues [181,182]. Excess polymerized HGA deposits within various cells types including endothelial cells, macrophages, fibroblasts and smooth muscle cells. In patients with alkaptonuria, pigment occurs in heart valves, healed myocardial infarcts, atherosclerotic vascular lesion, and throughout non-atherosclerotic arterial walls. [182-186].

Pathophysiology: Cardiac manifestations is very rare with ochronosis described in heart valves, aorta, pericardium, endocardium and coronary arteries [180,187,188]. Two frequently described pathological features associated with ochronotic cardiac involvement are aortic stenosis and coronary artery calcification. Aortic stenosis is the most common cardiac manifestation with a number of case reports describing an increase in the prevalence of aortic stenosis in comparison to the general population [180]. In the Cardiovascular Health Study enrolling 5,621 patients (≥ 65 years), 1.8% had aortic stenosis [189] while in a series of 76 patients with alkaptonuria, 25% of patients (≥ 65 years) had aortic stenosis [190]. In a recent review of 175 cases of alkaptonuria, 35% had aortic valve disease, 19% aortic stenosis, 11% aortic regurgitation and 5% aortic valve disease or aortic valve replacement for unspecified reasons [180].

The pathogenesis of cardiac manifestations in ochronotic patients is unclear, although several theories have been proposed. It is hypothesized that ochronotic pigment is initially deposited in fibrocytes, macrophages, smooth muscle cells and the extracellular matrix. These pigment-laden cells degenerate to release the pigment extracellularly acting as a chemical irritant to produce a pro-inflammatory reaction or as a direct enzyme inhibitor that causes alteration in cartilage metabolism resulting in dystrophic calcification and fibrosis of the cardiac valve leaflets [191]. The predominant presence of ochronotic deposition in areas of turbulent flows where there are eddy current such as in sinotubular junction, which plays a role in diastolic coronary filling. This may explain the deposition of ochronotic pigment in the ostia of the coronary arteries and aortic valve leaflets whereas there is minimal deposition in venous circulation [180]. Thus, vascular flow dynamics dictate the site of pigment deposition resulting in subsequent microvascular injury [192].

Clinical evaluation: Diagnosis for ochronotic CM lacks well-defined guidelines. In literature, only a handful of case reports have described diagnosis of cardiac involvement in ochronotic patients. The classic clinical triad of ochronosis is (i) homogentisic aciduria (urine blackens on standing when oxidized or alkalized); (ii) eumelanin-like pigmentation of skin, sclera, cartilages; and (iii) degenerative ochronotic arthropathies usually manifesting in the fourth decade of life due to decline in renal clearance with age [185]. There is a wide
clinical variable among patients that may be explained by 84 different mutations identified in the HGO gene. Patients also exhibit different rate of renal clearance [180]. Cardiac disease can have a significant impact on ochronotic patients and thus if a patient is diagnosed there is a growing consensus for echocardiographic screening after the age of 40 years to detect cardiac involvement and cardiac gated CT to assess coronary artery calcification.

Several case reports have reported different pathologic features associated with ochronotic CM with the involvement of the aorta, coronary vessels and heart valves. The pericardium may be involved in elderly patients [183-186]. In a case report of a 78-year old male patient with known alkaptonuria and severe symptomatic aorta, pathologic examination of the aortic valve and the ascending aorta revealed intracellular and extracellular deposits of ochronotic pigments. The extracellular deposits partially represent degenerated cells appearing as valvular calcifications [183]. In the case of a 35-year old male patients presenting with persistent hip and low-back pain non-responsive to NSAIDs and physiotherapy, laboratory findings reveal normal erythrocyte sedimentation rate (ESR), C-reactive protein (CRP). Heart echocardiography revealed intraventricular septum and posterior wall hypertrophy (13.3 mm, 12 mm), thickening of the aortic cusps with calcification, moderate decreased opening and mild aortic insufficiency [185]. The atherosclerotic process is accelerated by the deposition of ochronotic pigment, and a frequent mode of death in patients with alkaptonuria is myocardial infarction [186].

Clinical management: Currently, there is no reliable therapy for ochronosis. Nitisinone, a potent inhibitor of the HGO enzyme that produces HGA, which has shown effectiveness in reducing HGA levels in alkaptonuria [185]. In a small trial enrolling 18 patients treated for 3 years with nitisinone. Aortic valve dysfunction (aortic valve velocities > 0.3m/s) was reported in four (4) patents in the treatment arm and one (1) in the control arm. Although the small sample was difficult to draw reliable conclusions but suggest the effect may be maximized if treatment begun early [193]. Other studies report nitisinone-associated marked increase in tyrosine levels that can potentially lead to corneal irritation, dermatological and neurological side effects and long-term effect of nitisinone remains uncertain [179,194]. Attempts to treat alkaptonuria with high dose vitamin C and dietary restriction of tyrosine and phenylamine intake failed to produce a decrease in HGA levels [195]. Currently, the standard therapy consists of a diet low in phenylalanine and tyrosine, and targeted therapy for cardiac symptoms as per the current HF guidelines [180]. Cardiac surgery may be considered in older ochronotic patients (48-67 years) with calcified aortic valves but long-term effect of surgical intervention have not been investigated [180].

Meta-analysis of diagnosis

A meta-analysis was conducted to evaluate the current diagnostic methods and features for CM due to deposition diseases. Studies of interest were those that assessed patients with known or suspected deposition diseases that can cause CM. Online databases PubMed, Embase and Google Scholar were searched to identify relevant studies. Key words used for the search included deposition diseases (amyloidosis, haemochromatosis, oxalosis and ochronosis), diagnosis or prognosis, (echocardiography, ECG or cardiac MRI. There was no language or publication date restriction. The inclusion criteria were studies evaluating the diagnostic and/or prognostic role of ECG, echocardiography and cardiac MRI in patients with CM due to deposition diseases. The exclusion criteria were studies that enrolled patients with ischemic and non-ischemic CM, acute myocarditis and hypertrophic and infiltrative CM. All abstracts and full-text report of articles meeting the inclusion criteria were retrieved and studied.

Findings: The online search query yielded 109 articles. Of these, only 18 articles that satisfied the inclusion criteria formed the final dataset for this meta-analysis [196-213]. Table 3 provides a summary of study characteristics and main findings. In total, the 18 studies enrolled 1,103 patients with biopsy proven cardiac amyloidosis (CA), older (mean age = 62 years; range = 47-73), and with a greater proportion of male patients based on sixteen studies [196,198-212] having 621:314 male to female ratio translating into 66.4% males. Ten of the studies [196-205] evaluated diagnostic and prognostic value of LGE-CMRI while the remaining eight evaluated the diagnostic value of echocardiography [206-213]. Of the ten CMRI studies, eight were prospective single-centre clinical trials [196,197,199,200,202-205], while the remaining two were retrospective single-centre studies [198,201]. All the CMRI patients had biopsy-proven cardiac amyloidosis and diagnostic LGE images.

In a pooled analysis of eight studies [196,198-201,203-205] evaluating cardiac MRI, 350 surviving patients out of 584 with biopsy proven CA showed the presence of LGE (LGE +ve) translating into an event rate (ER) of 56.5% (95% CI: 42.1 to 69.9: Figure 1). On the other hand, the number of surviving patients without any presence of LGE (LGE –ve) was 158 out of 584 (ER: 28.6%, 95% CI: 16.9 to 44.1: Figure 2). These findings suggest that LGE-CMRI might be a promising method to diagnose or to exclude CA obviating the need for invasive endomyocardial biopsy (EMB). The included CMRI studies also revealed prognostic value of LGE-CMRI. In seven cardiac MRI studies [196,198-201,203,204], there were 147 deaths out of 426 patients. The majority of deaths (n=129; 87.8%) were in patients positive for LGE compared to those negative for LGE (n=18; 12.2%). In addition, pooled analysis of the seven studies revealed a statistically significant four-fold higher odds for death in LGE +ve patients compared to LGE –ve patients (Odds Ratio [OR]: 4.062; 95% CI: 1.340 to 12.313; p=0.013: Figure 3).

Finally, a pooled analysis of five studies [197,198,200,201,203] revealed LGE- cardiac MRI has a high diagnostic sensitivity of 89% (95% CI: 82 to 94; Table 4) and diagnostic specificity of 88% (95% CI: 77 to 94; Table 5). Pooled positive predictive value was 92.1% (95% CI: 88.9 to 94.5%) and negative predictive value was 86.8% (95% CI: 71.7 to 94.5%). The most common ECG abnormality reported in seven studies [198,199,203,206,210,211,214] is low voltage observed in 171 out of 331 patients (event rate: 48.8%; 95% CI: 37.1 to 60.7%)

On echocardiography, the most common diagnostic features reported were markers for diastolic dysfunction: mitral inflow deceleration time (DT), peak early to late diastolic velocity (E/A) ratio and mitral annular septal velocity (E/E’ ratio). On echocardiography, patients with CA exhibit shorter DT and higher E/A ratios. In pooled DT data from seven studies [206-210,211,213] enrolling 292 patients showed mean DT of 175 ms (95% CI: 163 to 187 ms) and pooled E/A data from eight studies [206-213] enrolling 427 patients had mean E/A ratio of 1.93 (95% CI: 1.62 to 2.25). Compared with healthy controls, CA patients had significantly shorter mean DT (weighted mean difference [WMD]: -28.16; 95% CI: -55.94 to -0.374; p = 0.047; Figure 5) and a tendency towards a higher E/A ratio (WMD: 0.37; 95% CI: -0.17 to 0.92; p = 0.18; Figure 6) in four studies [206-209]. Significantly more CA patients had E/E’ ratio > 15 and DT < 160 ms compared to healthy controls or LGE -ve patients [198,203].
Table 3. Characteristics of included studies

<table>
<thead>
<tr>
<th>Author [Ref #]</th>
<th>Year</th>
<th>Study Design</th>
<th>No. of Patients</th>
<th>Mean Age (yrs.)</th>
<th>M/F Ratio</th>
<th>Diagnostic Tests</th>
<th>Summary of Key Clinical and Imaging Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vogelsberg [197]</td>
<td>2008</td>
<td>Prospective single center</td>
<td>33</td>
<td>64±13</td>
<td>NA</td>
<td>LGE-CMRI</td>
<td>LGE-CMRI can be used to diagnose or rule out CA with good sensitivity and excellent specificity in a clinical setting.</td>
</tr>
<tr>
<td>Austin [198]</td>
<td>2009</td>
<td>Retrospective single center</td>
<td>47</td>
<td>62(51-75)</td>
<td>33/14</td>
<td>LGE-CMRI</td>
<td>LGE-CMRI pattern is more accurate for diagnosis and a stronger predictor of one-year mortality.</td>
</tr>
<tr>
<td>Migrino [199]</td>
<td>2009</td>
<td>Prospective single center</td>
<td>29</td>
<td>62±11.5</td>
<td>15/14</td>
<td>LGE-CMRI</td>
<td>LGE is common and associated with poor long-term prognosis in CA patients and may be useful for risk stratification.</td>
</tr>
<tr>
<td>Ruberg [200]</td>
<td>2009</td>
<td>Prospective single center</td>
<td>28</td>
<td>62±11</td>
<td>20/8</td>
<td>LGE-CMRI</td>
<td>LGE is highly sensitive and specific for the identification of cardiac involvement but does not predict survival.</td>
</tr>
<tr>
<td>Mekinian [201]</td>
<td>2010</td>
<td>Retrospective single center</td>
<td>29</td>
<td>63±11</td>
<td>19/10</td>
<td>LGE-CMRI</td>
<td>Positive CMRI is associated with a significantly increased risk of death but not independent of clinical HF.</td>
</tr>
<tr>
<td>Aquaro [202]</td>
<td>2014</td>
<td>Prospective single center</td>
<td>59</td>
<td>69±10</td>
<td>36/23</td>
<td>LGE-CMRI</td>
<td>Global hyper-enhancement in CMRI accurately identifies patients with biopsy proven CA and a strong predictor of mortality.</td>
</tr>
<tr>
<td>White [203]</td>
<td>2014</td>
<td>Prospective single center</td>
<td>90</td>
<td>62±13</td>
<td>52/38</td>
<td>LGE-CMRI</td>
<td>Transmural LGE shows a continuum of cardiac involvement in CA patients.</td>
</tr>
<tr>
<td>Fontana [204]</td>
<td>2015</td>
<td>Prospective single center</td>
<td>250</td>
<td>67±12</td>
<td>181/69</td>
<td>LGE-CMRI</td>
<td>Transmural LGE shows a continuum of cardiac involvement in CA patients.</td>
</tr>
<tr>
<td>Lin [205]</td>
<td>2018</td>
<td>Prospective single center</td>
<td>82</td>
<td>55.5±8.5</td>
<td>52/30</td>
<td>LGE-CMRI</td>
<td>Both LGE and ECV are independent prognostic for mortality in CA patients.</td>
</tr>
<tr>
<td>Klein [206]</td>
<td>1989</td>
<td>Prospective single center</td>
<td>53</td>
<td>60±12</td>
<td>37/16</td>
<td>LGE-CMRI</td>
<td>CA exhibits a spectrum of diastolic filling abnormalities but the restrictive filling pattern is seen only in the advanced disease stages.</td>
</tr>
<tr>
<td>Klein [207]</td>
<td>1990a</td>
<td>Prospective single center</td>
<td>41</td>
<td>58±10</td>
<td>28/13</td>
<td>LGE-CMRI</td>
<td>RV diastolic function is abnormal in CA and restrictive filling patterns manifests in the later stages of the disease.</td>
</tr>
<tr>
<td>Klein [208]</td>
<td>1990b</td>
<td>Prospective single center</td>
<td>41</td>
<td>59±11</td>
<td>36/15</td>
<td>LGE-CMRI</td>
<td>Serial left ventricular flow velocity variables occur during short-term follow-up evaluation predominantly in the early group with CA.</td>
</tr>
<tr>
<td>Tei [209]</td>
<td>1996</td>
<td>Prospective single center</td>
<td>45</td>
<td>60±10</td>
<td>29/16</td>
<td>LGE-CMRI</td>
<td>Doppler-derived index of combined systolic and diastolic dysfunction correlates with global cardiac dysfunction and is a useful predictor of clinical outcomes in CA.</td>
</tr>
<tr>
<td>Dubrey [210]</td>
<td>1997</td>
<td>Prospective single center</td>
<td>36</td>
<td>47±11</td>
<td>23/13</td>
<td>LGE-CMRI</td>
<td>Cardiac involvement in AL and familial CA is indistinguishable but preservation of ECG voltage in familial CA suggest biochemical properties of different types of amyloid fibrils exert different pathological effect, which becomes important in evaluation, management and treatment of different types of CA.</td>
</tr>
<tr>
<td>Ng (SSA) [211]</td>
<td>2005</td>
<td>Prospective single center</td>
<td>18</td>
<td>73±5</td>
<td>18/0</td>
<td>Serum markers, ECG, Echo - 2D, Doppler</td>
<td>LV wall thickness in AL is greater than in SSA patients but severity of HF in AL is less than in SSA group who have much longer survival.</td>
</tr>
<tr>
<td>Ng (AL) [211]</td>
<td>2005</td>
<td>Prospective single center</td>
<td>18</td>
<td>57±9</td>
<td>11/7</td>
<td>Echo - 2D, Doppler</td>
<td>Cardiac involvement in AL and familial CA is indistinguishable but preservation of ECG voltage in familial CA suggest biochemical properties of different types of amyloid fibrils exert different pathological effect, which becomes important in evaluation, management and treatment of different types of CA.</td>
</tr>
<tr>
<td>Pinney (AL) [212]</td>
<td>2013</td>
<td>Prospective single center</td>
<td>36</td>
<td>63</td>
<td>NA</td>
<td>Echo - 2D, Doppler</td>
<td>Older age at diagnosis and lower NT-proBNP level can help distinguish ATTR from AL CA. Positive troponin T, pacemaker and NYHA class symptoms suggest poor prognosis in ATTR patients.</td>
</tr>
<tr>
<td>Pinney (ATTR) [212]</td>
<td>2013</td>
<td>Prospective single center</td>
<td>99</td>
<td>73</td>
<td>NA</td>
<td>Echo - 2D, Doppler</td>
<td>Older age at diagnosis and lower NT-proBNP level can help distinguish ATTR from AL CA. Positive troponin T, pacemaker and NYHA class symptoms suggest poor prognosis in ATTR patients.</td>
</tr>
<tr>
<td>Pagourelas [213]</td>
<td>2017</td>
<td>Prospective single center</td>
<td>40</td>
<td>65.5±10.8</td>
<td>26/14</td>
<td>Echo, Clinical parameters</td>
<td>Thickened hearts, EF global longitudinal strain ratio has the best accuracy in detecting CA even in patients with mild hypertrophy and preserved EF.</td>
</tr>
</tbody>
</table>

**Table 4. Pooled sensitivity for LGE diagnosis for cardiac amyloidosis**

<table>
<thead>
<tr>
<th>Study (Author)</th>
<th>Sensitivity (%)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vogelsberg [197]</td>
<td>80</td>
<td>71 to 87</td>
</tr>
<tr>
<td>Austin [198]</td>
<td>88</td>
<td>80 to 93</td>
</tr>
<tr>
<td>Ruberg [200]</td>
<td>86</td>
<td>77 to 91</td>
</tr>
<tr>
<td>Mekinian [201]</td>
<td>98</td>
<td>92 to 99</td>
</tr>
<tr>
<td>White [203]</td>
<td>93</td>
<td>86 to 96</td>
</tr>
<tr>
<td>Pooled Sensitivity</td>
<td>89</td>
<td>82 to 94</td>
</tr>
</tbody>
</table>

**Abbreviations:** AL: Light-chain Amyloidosis; ATTR: Amyloidosis Transthyretin; CA: Cardiac Amyloidosis; CMRI: Cardiac Magnetic Resonance Imaging; ECG: Electrocardiogram; Echo: Echocardiography; LGE: Late Gadolinium Enhancement; LV: Left Ventricular; NYHA: New York Heart Association; SSA: Systemic Senile Amyloidosis.
Albakri A (2019) Deposition diseases cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

Figure 1. Percentage of biopsy-Proven CA patients with the presence of LGE

Figure 2. Percentage of biopsy-proven CA patients without the presence of LGE

Figure 3. Odds ratio for all-cause mortality in LGE +ve versus LGE -ve patients
Albakri A (2019) Deposition diseases cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

Table 5. Pooled specificity for LGE diagnosis for cardiac amyloidosis

<table>
<thead>
<tr>
<th>Study (Author)</th>
<th>Specificity (%)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vogelsberg [197]</td>
<td>94</td>
<td>87 to 97</td>
</tr>
<tr>
<td>Austin [198]</td>
<td>90</td>
<td>82 to 94</td>
</tr>
<tr>
<td>Ruberg [200]</td>
<td>86</td>
<td>77 to 91</td>
</tr>
<tr>
<td>Mekinian [201]</td>
<td>86</td>
<td>86 to 96</td>
</tr>
<tr>
<td>White [203]</td>
<td>70</td>
<td>70 to 78</td>
</tr>
<tr>
<td>Pooled Specificity</td>
<td>88</td>
<td>77 to 94</td>
</tr>
</tbody>
</table>

Inconsistency: I² = 84.96%; p = 0.000

Figure 4. Event rate for low voltage on ECG

Figure 5. Mean difference in DT between study and treatment groups

Figure 6. Mean difference in EA ratio between study and treatment groups
Discussion

The role of cardiac imaging and serum levels of cardiac biomarkers have been well documented both in the diagnosis and prognosis of specific types of CMs, particularly in morphologically classified dilated, hypertrophic and restrictive CMs. However, the role of cardiac imaging in the diagnosis and prognosis of CMs due to deposition diseases remains unclear partly because specific studies on deposition diseases with cardiac involvement are sporadic and largely based on case reports. The present meta-analysis sought to evaluate the diagnosis and prognosis of CM associated with deposition diseases. However, in the online search for studies, it became apparent that except for amyloid CMs, the other forms of CM-associated deposition diseases such as haemochromatosis, oyalosis and ochronosis lack specific large-scale clinical trials. In the end, clinical studies included in this meta-analysis only evaluated patients with CMs due to amyloidosis leading to an incomplete understanding of diagnostic features potentially shared by deposition diseases CMs. Understanding deposition diseases CMs is clinically relevant since patients usually have a poor prognosis, and early diagnosis and prompt institution of treatment is essential to improve clinical outcomes. Despite the limitation of data on deposition disease CM, the findings of the current meta-analysis raise important findings about the diagnostic and prognostic role of echocardiography and cardiac MRI, which is consistent with and supports four previous meta-analyses on CA [214-217] and expert consensus on the diagnosis and cardiac MRI, which is consistent with and supports four previous meta-analyses on CA [214-217] and expert consensus on the diagnosis and prognosis of other deposition diseases.

Clinical implications: Cardiomyopathy associated with deposition diseases often has a poor prognosis. Thus, better diagnostic tests might permit earlier detection and targeted intervention to improve clinical and patient outcomes [3]. At present, the most common methods used in the diagnosis of CMs are ECG and echocardiography due to widespread availability, ease of use and convenience. However, both methods have little use in CMs due to deposition diseases because of low detection accuracy in the early stages of the disease as well as lack pathognomonic features to confirm diagnosis in clinical practice that EMB is not in common use [214]. ECG evaluation is unsuitable for patients with pulmonary disorders yet many elderly CM patients are more likely to have cardiopulmonary involvement. Echocardiography on the other hand can only detect advanced cases but cannot easily assess earlier cases or differentiate certain deposition diseases such as CA from HCM because both have thickened ventricular walls with speckled myocardium [6, 218].

Although EMB is a gold standard in diagnosis of some deposition diseases such as CA because deposition occurs throughout the myocardial tissue [33-36], it is less useful in some deposition diseases such as haemochromatosis due to patchy deposition of iron on the myocardial tissues leading to many cases of false positive findings [134]. In addition, EMB has limited use in clinical settings due to unavailability, relatively high risks and clinical complications [214]. LGE-CMRI is thus emerging as an important non-invasive imaging technique to detect and quantify cardiac deposition to support diagnosis as well as acts as an independent diagnostic marker with a promise to obviate the need for invasive EMB in certain deposition diseases with cardiac involvement. However, there is a need for further clinical trials to confirm or identify other newer non-invasive imaging features to improve early diagnosis of CM due to deposition diseases to inform targeted treatment and improve clinical and patient outcomes.

Conclusion

Deposition diseases amyloidosis, haemochromatosis, oyalosis and ochronosis cause CM as a consequence of the accumulation of amyloid fibrils, iron, calcium oxalate and homogentisic acid respectively in
the myocardial tissues. Clinical presentation and diagnosis varies depending on the type of substance deposited, location and stage of the disease. Amyloid CM initially manifests as progressive diastolic dysfunction, and in the later stages of the disease, as biventricular dysfunction often accompanied by conduction disturbance. EMB remains the diagnostic gold standard while LGE-CMRI is an independent prognostic marker for mortality. Hemochromatosis initially manifests as restrictive hemodynamics and increased filling pressure, and then progresses into systolic dysfunction and biventricular dilatation. Cardiac MRI is the only non-invasive modality used to detect and quantify CM deposition in hemochromatosis patients while patchy iron deposits on the myocardium limits the diagnostic accuracy and the utility of EMB in clinical practice. Oxalosis principally manifests as kidney dysfunction with sinus tachycardia, AV block progressing into heart block, mildly diluted LV with moderately to severely depressed systolic function, biventricular concentric thickening with patchy echodense speckled myocardial reflections. Cardiac involvement is uncommon in ochronosis often manifesting as the calcification of aorta, coronary vessels and heart valves. Treatment usually targets the underlying disease: inhibiting amyloid fibril formation (amyloid), phlebotomy (haemochromatosis), vitamins and mineral therapy, and alkalinization of urine (oxalosis) and nitisinone (ochronosis).

References
8. Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112: 2047-2060. [Crossref]
19. Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the nerves. Brain 75: 408-427. [Crossref]
32. Stegman BM, Kwon D, Rodriguez ER, Hanna M, Cho L (2014) Left ventricular hypertrophy in a runner: things are not always what they seem. Circulation 130: 590-592. [Crossref]

38. Sperry BW, Vranian MN, Hackamovich R (2016) Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. *Int J Cardiol* 214: 477-481. [Crossref]


40. Miani D, Rocco M, Alberti E, Spedicato L, Fioretti PM (2002) Amyloidosis of epicardial and intramural coronary arteries as an unusual cause of myocardial infarction and refractory angina pectoris. * Ital Heart J* 3: 479-482. [Crossref]


42. Swanton RH, Brookshy JAB, Davies MJ, Cotart DJ, Jenkins BS, et al. (1977) Systolic and diastolic ventricular function in cardiac amyloidosis: studies in six cases diagnosed with endomyocardial biopsy. *Am J Cardiol* 39: 658-664. [Crossref]


55. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, et al. (2009) Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. *Blood* 114: 4957-4959. [Crossref]


60. Pollak A, Falk RH (1993) Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. *Chest* 104: 618-620. [Crossref]


114. Kremastinos DT (2001) Heart failure in beta-thalassemia. Congest Heart Fail 7: 312-314. [Crossref]
116. Skinner C, Kenmare AC. (1973) Haemochromatosis presenting as congestive cardiomyopathy and responding to venesection. Br Heart J 35: 456-466. [Crossref]
123. Rose RA, Sellan M, Simpson JA (2011) Iron overload decreases CaV1.3 dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation. Circ Arrhythm Electrophysiol 11: 174-177. [Crossref]


156. Chou LY, Donohue WL (1952) Oxalosis: possible” inborn error of metabolism” with nephrolithiasis and nephrocalcinosis due to calcium oxalate as the predominating stone. *Am J Med* 70: 2496-. [Crossref]


162. Coltart DJ, Hudson RE (1971) Primary oxalosis of the heart: a cause of heart block. *Br Heart J* 33: 315. [Crossref]


173. West RR, Salyer WR, Hutchinson GM (1973) Adult-onset primary oxalosis with cardiomypathy and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. *Circulation* 132: e273-e280. [Crossref]


198. Austin BA, Tang WH, Rodriguez ER (2009) Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. J Am Coll Cardiol 52: 1012-1030. [Crossref]


201. Ruberg FL, Appelbaum E, Daviddoff R (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103: 544-549. [Crossref]


204. White JA, Kim HW, Shah D (2014) CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. J Am Coll Cardiol Img 7: 143-156. [Crossref]


209. Klein AL, Hatle LK, Taliercio CL, Taylor CL, Kyle RA, et al. (1990b) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16: 1135-1141. [Crossref]


211. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH (1997) Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78: 74-82. [Crossref]


